FDA panel votes on Pfizer and GSK RSV vaccines

"On Tuesday, the panel voted in favor of the Pfizer vaccine by 7 to 4, with one abstention, on its safety and efficacy. On Wednesday, it voted 10 to 2 in favor of the GSK vaccine’s safety and unanimously on the shot’s efficacy."

https://www.nytimes.com/2023/03/01/health/rsv-vaccine-fda.html?action=click&module=Well&pgtype=Homepage&section=Health